IBDEI0PR ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12335,2)
 ;;=^323613
 ;;^UTILITY(U,$J,358.3,12336,0)
 ;;=V76.47^^62^738^86
 ;;^UTILITY(U,$J,358.3,12336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12336,1,3,0)
 ;;=3^V76.47
 ;;^UTILITY(U,$J,358.3,12336,1,4,0)
 ;;=4^Special Screening for vaginal Malignant Neoplasms
 ;;^UTILITY(U,$J,358.3,12336,2)
 ;;=^322085
 ;;^UTILITY(U,$J,358.3,12337,0)
 ;;=V45.77^^62^738^8
 ;;^UTILITY(U,$J,358.3,12337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12337,1,3,0)
 ;;=3^V45.77
 ;;^UTILITY(U,$J,358.3,12337,1,4,0)
 ;;=4^Acquired Absence of Uterus
 ;;^UTILITY(U,$J,358.3,12337,2)
 ;;=^322067
 ;;^UTILITY(U,$J,358.3,12338,0)
 ;;=233.1^^62^738^19
 ;;^UTILITY(U,$J,358.3,12338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12338,1,3,0)
 ;;=3^233.1
 ;;^UTILITY(U,$J,358.3,12338,1,4,0)
 ;;=4^CA in Situ (Sev. Dysplasia)
 ;;^UTILITY(U,$J,358.3,12338,2)
 ;;=^267736
 ;;^UTILITY(U,$J,358.3,12339,0)
 ;;=789.00^^62^738^1
 ;;^UTILITY(U,$J,358.3,12339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12339,1,3,0)
 ;;=3^789.00
 ;;^UTILITY(U,$J,358.3,12339,1,4,0)
 ;;=4^Abdom Pain, Unsp Site
 ;;^UTILITY(U,$J,358.3,12339,2)
 ;;=^303317
 ;;^UTILITY(U,$J,358.3,12340,0)
 ;;=795.09^^62^738^2
 ;;^UTILITY(U,$J,358.3,12340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12340,1,3,0)
 ;;=3^795.09
 ;;^UTILITY(U,$J,358.3,12340,1,4,0)
 ;;=4^Abn Pap Cervix HPV NEC
 ;;^UTILITY(U,$J,358.3,12340,2)
 ;;=^331974
 ;;^UTILITY(U,$J,358.3,12341,0)
 ;;=V45.77^^62^738^7
 ;;^UTILITY(U,$J,358.3,12341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12341,1,3,0)
 ;;=3^V45.77
 ;;^UTILITY(U,$J,358.3,12341,1,4,0)
 ;;=4^Acq Absence Org,Genitals
 ;;^UTILITY(U,$J,358.3,12341,2)
 ;;=^322067
 ;;^UTILITY(U,$J,358.3,12342,0)
 ;;=215.9^^62^738^16
 ;;^UTILITY(U,$J,358.3,12342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12342,1,3,0)
 ;;=3^215.9
 ;;^UTILITY(U,$J,358.3,12342,1,4,0)
 ;;=4^Ben Neo Soft Tissue NOS
 ;;^UTILITY(U,$J,358.3,12342,2)
 ;;=^267620
 ;;^UTILITY(U,$J,358.3,12343,0)
 ;;=221.2^^62^738^17
 ;;^UTILITY(U,$J,358.3,12343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12343,1,3,0)
 ;;=3^221.2
 ;;^UTILITY(U,$J,358.3,12343,1,4,0)
 ;;=4^Benign Neoplasm Vulva
 ;;^UTILITY(U,$J,358.3,12343,2)
 ;;=^267650
 ;;^UTILITY(U,$J,358.3,12344,0)
 ;;=795.05^^62^738^20
 ;;^UTILITY(U,$J,358.3,12344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12344,1,3,0)
 ;;=3^795.05
 ;;^UTILITY(U,$J,358.3,12344,1,4,0)
 ;;=4^Cervical (HPV) DNA POS
 ;;^UTILITY(U,$J,358.3,12344,2)
 ;;=^331573
 ;;^UTILITY(U,$J,358.3,12345,0)
 ;;=701.0^^62^738^23
 ;;^UTILITY(U,$J,358.3,12345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12345,1,3,0)
 ;;=3^701.0
 ;;^UTILITY(U,$J,358.3,12345,1,4,0)
 ;;=4^Circumscribe Scleroderma
 ;;^UTILITY(U,$J,358.3,12345,2)
 ;;=^108577
 ;;^UTILITY(U,$J,358.3,12346,0)
 ;;=618.01^^62^738^29
 ;;^UTILITY(U,$J,358.3,12346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12346,1,3,0)
 ;;=3^618.01
 ;;^UTILITY(U,$J,358.3,12346,1,4,0)
 ;;=4^Cystocele, Midline
 ;;^UTILITY(U,$J,358.3,12346,2)
 ;;=^331534
 ;;^UTILITY(U,$J,358.3,12347,0)
 ;;=621.30^^62^738^38
 ;;^UTILITY(U,$J,358.3,12347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12347,1,3,0)
 ;;=3^621.30
 ;;^UTILITY(U,$J,358.3,12347,1,4,0)
 ;;=4^Endometrial Hyperplas NOS
 ;;^UTILITY(U,$J,358.3,12347,2)
 ;;=^331542
 ;;^UTILITY(U,$J,358.3,12348,0)
 ;;=626.2^^62^738^41
 ;;^UTILITY(U,$J,358.3,12348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12348,1,3,0)
 ;;=3^626.2
 ;;^UTILITY(U,$J,358.3,12348,1,4,0)
 ;;=4^Excessive Menstrauation
 ;;^UTILITY(U,$J,358.3,12348,2)
 ;;=^75895
 ;;^UTILITY(U,$J,358.3,12349,0)
 ;;=V16.41^^62^738^42
 ;;^UTILITY(U,$J,358.3,12349,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI0PR
